Both groups demonstrated efficacy through @weeks of treatment relative to baseline pretabalumab disease activity based on American College of Rheumatology criteria improvement @ % , @ % and @ % ; European League against Rheumatism Responder Index in @ joints ; Disease Activity Score in @ joints-C-reactive protein ; and Health Assessment Questionnaire-Disability Index .